CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CG Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$59.96+0.11 (+0.18%)
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
94M of 89M shares
Institutional holders
227
34 new, 37 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
1 buys · 15 sales
Net bought $20.04M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RTW Investments, LP | 8,514,590 | 9.70% | 13G (passive) amendment | Jun 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 6,720,389 | 8.00% | 13G (passive) | Mar 31, 2026 |
| Xiangmin Cui | 6,371,669 | 8.40% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 6,023,696 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Company LLP | 5,512,779 | 6.90% | 13G (passive) | Sep 30, 2025 |
| Wellington Management Group LLP | 5,324,751 | 6.00% | 13G (passive) amendment | Jun 30, 2026 |
| Juliet Tammenoms Bakker | 4,662,268 | 6.00% | 13D (active) | Sep 11, 2025 |
| SONG, Hong Fang | 4,211,341 | 5.50% | 13G (passive) amendment | Dec 31, 2024 |
| FMR LLC | 3,856,261 | 5.10% | 13G (passive) | Jun 30, 2025 |
| Kissei Pharmaceutical Co., Ltd. | 3,543,533 | 5.30% | 13G (passive) | Jan 29, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CGON | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 8,514,590 | 9.61% | $604.96M | +1,529,782 | 5.16% |
| T. Rowe Price Investment Management, Inc. | 6,616,899 | 7.46% | $470.13K | −103,490 | 0.31% |
| Decheng Capital LLC | 6,371,669 | 7.19% | $452.71M | – | 61.87% |
| BlackRock, Inc. | 6,256,288 | 7.06% | $444.51M | +1,192,108 | 0.01% |
| Wellington Management Group Llp | 5,324,751 | 6.01% | $378.32M | −46,481 | 0.07% |
| FMR LLC | 4,161,493 | 4.69% | $295.67M | +396,649 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 3,805,010 | 4.29% | $270.35K | +152,030 | 0.03% |
| TCG Crossover Management, LLC | 3,670,206 | 4.14% | $260.77M | – | 6.27% |
| Vanguard Portfolio Management LLC | 3,465,197 | 3.91% | $246.20M | +370,099 | 0.01% |
| State Street Corp | 3,437,590 | 3.88% | $244.24M | +790,536 | 0.01% |
| Vanguard Capital Management LLC | 3,316,793 | 3.74% | $235.66M | +283,168 | 0.01% |
| Foresite Capital Management VI LLC | 2,369,574 | 2.67% | $168.36M | +148,100 | 26.20% |
| Geode Capital Management, LLC | 2,153,277 | 2.43% | $153.02M | +556,413 | 0.01% |
| Seven Fleet Capital Management LP | 1,886,236 | 2.13% | $134.02M | +1,810,478 | 22.12% |
| EcoR1 Capital, LLC | 1,494,300 | 1.69% | $106.17M | +392,300 | 5.16% |
| DV Trading LLC | 1,439,393 | 1.62% | $102.27M | – | 3.35% |
| Avidity Partners Management LP | 1,398,948 | 1.58% | $99.40M | +110,000 | 15.92% |
| Alliancebernstein L.P. | 1,374,149 | 1.55% | $93.00M | +84,062 | 0.03% |
| Franklin Resources Inc | 1,312,880 | 1.48% | $93.28M | −194,125 | 0.02% |
| Morgan Stanley | 1,177,109 | 1.33% | $83.63M | +656,896 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 227 | 94M | 100.0% | 34 / 93 | 72 / 37 | 14M | 8M |
| Q1 2026 | 233 | 88M | 99.7% | 65 / 81 | 61 / 23 | 25M | 13M |
| Q4 2025 | 195 | 83M | 93.3% | 43 / 72 | 50 / 20 | 14M | 9M |
| Q3 2025 | 176 | 78M | 87.9% | 34 / 54 | 57 / 19 | 9M | 7M |
| Q2 2025 | 162 | 76M | 85.7% | 40 / 76 | 29 / 19 | 14M | 9M |
| Q1 2025 | 142 | 71M | 79.8% | 27 / 62 | 33 / 24 | 8M | 3M |
| Q4 2024 | 140 | 66M | 74.7% | 37 / 59 | 27 / 17 | 19M | 5M |
| Q3 2024 | 121 | 52M | 58.9% | 26 / 60 | 19 / 15 | 15M | 4M |
| Q2 2024 | 111 | 43M | 48.8% | 32 / 45 | 18 / 17 | 10M | 6M |
| Q1 2024 | 96 | 39M | 43.9% | 96 / 0 | 0 / 0 | 39M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CGON | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2,860,428 | 3.23% | $203.63M | 0.53% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,574,868 | 2.90% | $182.94M | 0.26% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,383,134 | 2.69% | $169.32M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,894,091 | 2.14% | $134.58M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,812,932 | 2.05% | $128.81M | 1.20% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,720,068 | 1.94% | $122.21M | 0.06% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,114,695 | 1.26% | $79.20M | 0.54% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 860,026 | 0.97% | $61.10M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 806,808 | 0.91% | $57.44M | 0.17% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 797,441 | 0.90% | $56.77M | 0.65% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 744,793 | 0.84% | $52.92M | 0.23% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 681,220 | 0.77% | $48.40M | 0.31% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 658,981 | 0.74% | $46.82M | 0.48% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 593,262 | 0.67% | $42.15M | 0.28% | Jun 30, 2026 |
| Small Cap Growth Fund | 554,416 | 0.63% | $39.47M | 0.71% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Arthur Kuan | Chief Executive Officer, Director | 200,763 | 0.23% | Apr 16, 2026 |
| Joshua F. Patterson | See Remarks | – | – | Apr 16, 2026 |
| James M. Detore | Chief Financial Officer | – | – | Apr 16, 2026 |
| Ambaw Bellete | President and COO | – | – | Apr 16, 2026 |
| Vijay Kasturi | Chief Medical Officer | 1,315 | 0.00% | Apr 16, 2026 |
| Bob Lapetina | See Remarks | – | – | Aug 6, 2025 |
| Corleen M. Roche | CFO | 2,000 | 0.00% | Apr 16, 2025 |
| Leonard E. Post | Director | 0 | – | Sep 17, 2026 |
| James Mulay | Director | 0 | – | Jul 14, 2026 |
| Brian Guan-Chyun Liu | Director | 1,886,236 | 2.13% | Jun 29, 2026 |
| Susan E. Graf | Director | – | – | Jun 5, 2026 |
| Victor Edward Tong Jr | Director | – | – | Jun 5, 2026 |
| Christina Rossi | Director | – | – | Jun 5, 2026 |
| Hong Fang Song | Director | 7,039,077 | 7.94% | Sep 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Leonard E. Post Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,000 | $72.98 | $72.98K | 0 |
| Leonard E. Post Director | Sep 15, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Aug 14, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Aug 14, 2026 | Sale(10b5-1 plan) | −1,000 | $74.54 | $74.54K | 0 |
| Leonard E. Post Director | Jul 15, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Jul 15, 2026 | Sale(10b5-1 plan) | −1,000 | $71.17 | $71.17K | 0 |
| James Mulay Director | Jul 10, 2026 | Sale(10b5-1 plan) | −24,165 | $75.16 | $1.82M | 0 |
| James Mulay Director | Jul 10, 2026 | Option exercise | +24,165 | $26.63 | $643.51K | 24,165 |
| Brian Guan-Chyun Liu Director | Jun 25, 2026 | Buy | +371,085 | $66.87 | $24.81M | 1,886,236 |
| Leonard E. Post Director | Jun 24, 2026 | Option exercise | +5,000 | $0.60 | $3.00K | 5,000 |
| Leonard E. Post Director | Jun 24, 2026 | Sale(10b5-1 plan) | −5,000 | $70.00 | $350.00K | 0 |
| Leonard E. Post Director | Jun 22, 2026 | Option exercise | +5,000 | $0.60 | $3.00K | 5,000 |
| Leonard E. Post Director | Jun 22, 2026 | Sale(10b5-1 plan) | −5,000 | $65.00 | $325.00K | 0 |
| James Mulay Director | Jun 15, 2026 | Sale(10b5-1 plan) | −654 | $60.12 | $39.32K | 0 |
| James Mulay Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,310 | $60.12 | $78.76K | 0 |
| James Mulay Director | Jun 15, 2026 | Option exercise | +1,310 | $12.59 | $16.49K | 1,310 |
| James Mulay Director | Jun 15, 2026 | Option exercise | +654 | $3.72 | $2.43K | 654 |
| Leonard E. Post Director | Jun 4, 2026 | Sale(10b5-1 plan) | −1,000 | $54.50 | $54.50K | 0 |
| Leonard E. Post Director | Jun 4, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| James Mulay Director | Apr 17, 2026 | Sale(10b5-1 plan) | −15,600 | $73.01 | $1.14M | 0 |
| James Mulay Director | Apr 17, 2026 | Option exercise | +15,600 | $36.63 | $571.43K | 15,600 |
| James Mulay Director | Mar 16, 2026 | Sale(10b5-1 plan) | −1,310 | $63.50 | $83.19K | 0 |
| James Mulay Director | Mar 16, 2026 | Sale(10b5-1 plan) | −654 | $63.50 | $41.53K | 0 |
| James Mulay Director | Mar 16, 2026 | Option exercise | +654 | $3.72 | $2.43K | 654 |
| James Mulay Director | Mar 16, 2026 | Option exercise | +1,310 | $12.59 | $16.49K | 1,310 |
| Arthur Kuan Chief Executive Officer, Director | Mar 12, 2026 | Option exercise | +64,612 | $1.72 | $111.13K | 200,763 |
| Arthur Kuan Chief Executive Officer, Director | Mar 12, 2026 | Tax withholding | −1,847 | $60.15 | $111.10K | 198,916 |
| Arthur Kuan Chief Executive Officer, Director | Mar 4, 2026 | Tax withholding | −2,871 | $61.61 | $176.88K | 136,151 |
| Arthur Kuan Chief Executive Officer, Director | Mar 4, 2026 | Option exercise | +102,871 | $1.72 | $176.94K | 139,022 |
| James Mulay Director | Jan 9, 2026 | Option exercise | +10,491 | $12.59 | $132.08K | 10,491 |
| James Mulay Director | Jan 9, 2026 | Option exercise | +654 | $3.72 | $2.43K | 654 |
| James Mulay Director | Jan 9, 2026 | Sale(10b5-1 plan) | −654 | $44.16 | $28.88K | 0 |
| James Mulay Director | Jan 9, 2026 | Sale(10b5-1 plan) | −10,491 | $52.99 | $555.92K | 0 |
| Leonard E. Post Director | Nov 17, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Nov 17, 2025 | Sale(10b5-1 plan) | −1,000 | $41.43 | $41.43K | 0 |
| Leonard E. Post Director | Oct 13, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Oct 13, 2025 | Sale(10b5-1 plan) | −1,000 | $43.25 | $43.25K | 0 |
| James Mulay Director | Oct 9, 2025 | Option exercise | +5,903 | $3.72 | $21.96K | 5,903 |
| James Mulay Director | Oct 9, 2025 | Sale(10b5-1 plan) | −5,903 | $43.99 | $259.67K | 0 |
| Leonard E. Post Director | Sep 30, 2025 | Sale(10b5-1 plan) | −5,000 | $40.09 | $200.45K | 0 |
| Leonard E. Post Director | Sep 30, 2025 | Option exercise | +5,000 | $0.60 | $3.00K | 5,000 |
| James Mulay Director | Sep 29, 2025 | Sale(10b5-1 plan) | −12,755 | $39.19 | $499.87K | 0 |
| James Mulay Director | Sep 29, 2025 | Option exercise | +12,755 | $1.82 | $23.21K | 12,755 |
| James Mulay Director | Sep 19, 2025 | Sale(10b5-1 plan) | −3,574 | $38.99 | $139.35K | 0 |
| James Mulay Director | Sep 19, 2025 | Option exercise | +3,574 | $1.82 | $6.50K | 3,574 |
| James Mulay Director | Sep 18, 2025 | Sale(10b5-1 plan) | −19,112 | $39.01 | $745.56K | 0 |
| James Mulay Director | Sep 18, 2025 | Option exercise | +19,112 | $1.82 | $34.78K | 19,112 |
| Leonard E. Post Director | Sep 15, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Sep 15, 2025 | Sale(10b5-1 plan) | −1,000 | $35.10 | $35.10K | 0 |
| Brian Guan-Chyun Liu Director | Sep 11, 2025 | Buy | +1,515,151 | $33.00 | $50.00M | 1,515,151 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −12,342 | $30.47 | $376.06K | 14,673 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −4,095 | $31.42 | $128.66K | 10,578 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −7,465 | $32.64 | $243.66K | 3,113 |
| James Mulay Director | Sep 5, 2025 | Option exercise | +27,015 | $0.60 | $16.21K | 27,015 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −3,113 | $33.22 | $103.41K | 0 |
| Leonard E. Post Director | Sep 3, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Sep 3, 2025 | Sale(10b5-1 plan) | −1,000 | $28.00 | $28.00K | 0 |
| Hong Fang Song Director | Sep 3, 2025 | Sale(10b5-1 plan) | −100 | $28.99 | $2.90K | 2,903,931 |
| Hong Fang Song Director | Sep 3, 2025 | Sale(10b5-1 plan) | −100 | $28.96 | $2.90K | 2,904,031 |
| Hong Fang Song Director | Sep 3, 2025 | Sale(10b5-1 plan) | −30,105 | $28.24 | $850.17K | 2,904,131 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Post Leonard Director | Oct 15, 2026 | 3,000 | $185.52K | Oct 15, 2026 | Exercise of Stock Options |
| Bellete Ambaw Officer | Sep 21, 2026 | 30,787 | $2.34M | Sep 21, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Sep 17, 2026 | 6,532 | $499.70K | Sep 17, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Sep 11, 2026 | 826 | $61.95K | Sep 11, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Sep 2, 2026 | 29,630 | $2.30M | Sep 2, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 31, 2026 | 50,000 | $3.78M | Aug 31, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 27, 2026 | 5,789 | $459.56K | Aug 27, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 25, 2026 | 10,551 | $839.34K | Aug 25, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 24, 2026 | 5,762 | $458.19K | Aug 24, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 19, 2026 | 100,000 | $7.95M | Aug 19, 2026 | Exercised Shares |
| Bellete Ambaw Officer | Aug 17, 2026 | 52,438 | $4.03M | Aug 17, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 14, 2026 | 19,364 | $1.45M | Aug 14, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 13, 2026 | 25,989 | $1.97M | Aug 13, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 12, 2026 | 32,137 | $2.53M | Aug 12, 2026 | Stock Option Exercise |
| Bellete Ambaw Officer | Aug 11, 2026 | 50,000 | $3.81M | Aug 11, 2026 | Stock Option Exercise |